Blog

Team Category: Venture Network

Carlos Bustamante, PhD

Carlos Bustamante joined F-Prime in January 2019 as a Venture Partner based in the San Francisco office, and is focused on the application of data science and genomics technology to problems in medicine, agriculture, and biology. He is currently on leave from Stanford University where he is a Professor of Biomedical Data Science, Genetics, and (by courtesy) Biology, was founding Director of the Stanford Center for Computational, Evolutionary, and Human Genomics and is Inaugural Chair of the Department of Biomedical Data Science.

Carlos has a passion for building new academic units, non-profits, and companies to solve pressing scientific challenges. He is currently a Director at EdenRoc Sciences, LLC and Etalon DX, founder of Arc Bio, LLC and CDB Consulting LTD., and has served as an SAB member for more than a dozen companies.

Carlos received his PhD in Biology and MS in Statistics from Harvard University.

Josh Feinblum

Josh is a cofounder of Stavvy, a Boston-based fintech company, where he leads product, engineering, people, and finance. A lifelong technologist, Josh has focused on entrepreneurship, financial services, cybersecurity, privacy, and anti-fraud technology. Josh has been responsible for building and leading teams — from niche startups to large federal agencies — tackling some of the world’s largest fraud, abuse, and security challenges. Before Stavvy, he served as the Chief Security Officer (CSO) at DigitalOcean where he oversaw the legal operations, trust & safety, security, and fraud & abuse teams. Josh also launched Rapid7’s security organization, operating as the CSO he functioned as one of the corporate spokespeople and a member of the product leadership team. In addition to his operational background, Josh continues to serve as a professional advisor at the Martin Trust Center for MIT Entrepreneurship.

Josh earned his Bachelor’s degree from the University of Maryland and his MBA from the Sloan School of Management at MIT.

Mihir Shah

Mihir Shah is a veteran technology leader with over 30 years of experience in financial services and technology. He recently retired from Fidelity Investments, where he held several key leadership roles, including Chief Technology Officer (CTO), CIO – Enterprise Head of Data & Analytics, and Head of Enterprise Architecture. His core area of expertise is developing and executing on large, complex data and platform initiatives.

As CTO, Mihir led the modernization of Fidelity’s Asset Management platform, which now enables $5.6 trillion in assets under management. As Chief Data Officer (CDO), he spearheaded the development of a firm-wide, cloud-based data warehouse, unifying all data products into a single analytics platform. Earlier in his career, he played a pivotal role in enhancing Fidelity’s customer experience platforms, leading the rollout of CRM, Customer360, and Campaign Management by developing a unified data architecture for customer-facing channels.

Before Fidelity, Mihir led large-scale projects across the UK, Argentina, Singapore, and the US. He was the lead architect at Churchill Insurance in London, a pioneering startup in the UK insurance industry, and began his career at Tata Consultancy Services (TCS), contributing to its early growth.

In his post-retirement career, he is a Venture Partner at F-Prime Capital, Eight Roads Europe and India. He also serves as an Advisor in Residence to EY and is on advisory boards of numerous companies including Snowflake, Writer, Reltio, Skyflow, Promethium and Finbourne. He remains engaged in academia as an Industry Fellow at MIT Sloan School of Management.

Jay Farber

Jay Farber is a Venture Partner at F-Prime, where he leads early-stage investments in FinTech and SaaS companies. Jay joined F-Prime in 2015. He has led or participated in investments in Ashby, Papaya Payments, AvantStay, Quovo, Snapsheet, Vestwell, and System2.

Jay is also General Manager of the technology (GPX) business at Juniper Square, a leading institutional fund administrator and technology provider to VC, PE, and PERE funds. Juniper Square’s clients manage more than $1T in investor capital.

Jay is physically a Bay Area resident and culturally a Seattleite, but has invested across the country and does not hold the Patriots fandom of his F-Prime colleagues against them (mostly).

 

John Vigeant

John Vigeant is a Venture Partner with F-Prime and a recognized leader in the devops and security communities. John is VP, Americas for ObserveIT, the world’s #1 Insider Threat Management Solution. Previously John was CEO of Reddo Mobility, a code-less provider of enterprise mobility solutions for large enterprises and CEO of Tracelytics (acquired by AppNeta), a SaaS-based application performance management (APM) solution that provides deep visibility into the performance of distributed Web applications.

Earlier in his career, John led business development for XenSource until its acquisition by Citrix for $500M. John continued with Citrix until 2011 when he joined Reddo Mobility. John serves as an advisor to many early stage technology companies and is a valued resource to our portfolio companies on product strategy and operations.

Sanjay Aggarwal

Sanjay Aggarwal is a Venture Partner focused on physical and enterprise AI opportunities. His investments include Seyond (IPO on HKEX), Securonix (acquired by Vista Equity), Mineral Tree (acquired by Global Payments), Snapsheet, MoEngage, Whatfix, Burro, Teleo, Unbox Robotics, and RightHand Robotics. Prior to joining F-Prime, Sanjay was CEO of Unicel Technologies, an India-focused mobile messaging company, which was acquired by Karix Mobile.

Earlier in his career, Sanjay worked at Devonshire Investors (the private equity group of Fidelity Investments), McKinsey and Company in their US and India offices, and at Berkeley Process Control (acquired by Moog Inc), where he built machine automation systems. Sanjay holds a B.S. in Mechanical Engineering from MIT, an M.S. in Mechanical Engineering from UC Berkeley, and an M.B.A. from the MIT Sloan School of Management.

Stacie Weninger, PhD

Stacie Weninger, PhD, is a Venture Partner with F-Prime. She is a neuroscientist, biotech leader, and investor with more than 20 years of experience building, advising, and backing innovative neuroscience companies. She focuses on advancing neuroscience research and early-stage therapeutics through strategic collaboration, investment, and advisory roles, helping translate early scientific discoveries into novel medicines and build enduring companies.

Dr. Weninger served as President of the F-Prime Biomedical Research Initiative (FBRI), where she helped catalyze academic–industry collaboration and advance early neuroscience research toward therapeutic development.

Dr. Weninger currently serves as CEO and Chairman of the Board of Directors of Rugen Therapeutics and serves on the Boards of Aratome, Atalanta, Engrail, and Tenvie Therapeutics. She was a founding member of the Boards of Directors of Denali Therapeutics (NASDAQ: DNLI) and Neumora Therapeutics (NASDAQ: NMRA) and has held Board roles at numerous companies, including Annexon Biosciences (NASDAQ: ANNX), BRI-Alzan (acquired by MeiraGTx), Digital Cognition Technologies (acquired by Linus Health), Enspectra, Inscopix (acquired by Bruker Corporation), and Sironax.

In addition to her work in company creation and biotech investing, Dr. Weninger holds leadership and advisory roles across the neuroscience ecosystem. She serves on the Board of Target ALS, the Governing Board of the Michael J. Fox Foundation’s Targets to Therapeutics Initiative, and is a member of the Harvard Experts in Residence (XIR) network. Dr. Weninger is a member of numerous Scientific Advisory Boards, including those of Denali Therapeutics, the Breuer Foundation, Brown University’s Carney Center for Alzheimer’s Disease Research, the Harvard Blavatnik Biomedical Accelerator Fund, the Indian Institute of Science’s Centre for Brain Research, MIT’s Yang–Tan Center for Molecular Therapeutics, the External Advisory Board of Boston Children’s Hospital’s Rosamund Stone Zander Translational Neuroscience Center, and the UK Dementia Research Institute, among others. She also chairs the Collaboration for Alzheimer’s Prevention, which focuses on sharing learnings and best practices to accelerate clinical trials in early-stage Alzheimer’s disease. She previously served as President of Alzforum for more than a decade and continues as a special advisor.

Prior to joining F-Prime, Dr. Weninger was Senior Director of Science Programs at the Fidelity Foundations, where she oversaw biomedical research funding initiatives. Earlier in her career, she served as Project Manager and Senior Analyst for the Task Force on Women in Science at Harvard University and was a Senior Scientific Editor at Neuron (Cell Press). She began her scientific career as a postdoctoral research fellow in Dr. Bruce Yankner’s laboratory at Boston Children’s Hospital and Harvard Medical School.

Dr. Weninger received her PhD in neuroscience from Harvard University as a Howard Hughes Medical Institute predoctoral fellow and earned a B.S. in chemistry with highest honors from the University of North Carolina at Chapel Hill.